Published 23 October 2009, doi:10.1136/bmj.b4114
Cite this as: BMJ 2009;339:b4114

Clinical Review

Hyperkalaemia

¹ Endocrinology Unit, Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, ² Metabolic Unit, Western General Hospital, Lothian University Hospitals NHS Trust, Edinburgh

The first 150 words of the full text of this article appear below.

Hyperkalaemia is defined as serum potassium concentration greater than 5.5 mmol/l. Its prevalence in the general population is unknown, but it is thought to occur in 1-10% of patients admitted to hospital.¹ The rate of morbidity and mortality associated with hyperkalaemia has risen greatly with the use of drugs that target the renin-angiotensin system, and since publication 10 years ago of a randomised trial that showed that adding an aldosterone receptor antagonist to usual treatment for congestive failure improved outcomes.^{2 3 4 5}

We searched PubMed for articles whose titles included the terms "hyperkalaemia" or "potassium homoeostasis" and restricted the search to articles published in English in the past 15 years. We also searched contemporary textbooks.

Potassium is the most abundant cation in the human body and has key roles in the excitatory properties needed for conduction of nerve impulses and muscle contraction. Ninety eight per cent of the body’s potassium is in . . . [Full text of this article]

Potassium redistribution (intracellular to extracellular fluid)
Decreased excretion of potassium
Decreased urine flow rate or sodium delivery to distal nephron
Drugs that alter transmembrane potassium movement
Potassium containing agents
Drugs that reduce aldosterone secretion
Drugs that block aldosterone binding to mineralocorticoid receptor
Drugs that inhibit activity of epithelial sodium channel

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Benzylpenicillin potassium

Habib ur Rehman
BMJ 2009 339: b4822. [Extract] [Full Text]

Avoiding spurious hyperkalaemia

Rousseau Gama, Michael Cornes, and Clare Ford
BMJ 2009 339: b4823. [Extract] [Full Text]

Time to flag up "detox" drinks?

Christopher N Floyd
BMJ 2009 339: b4824. [Extract] [Full Text]

ABC of clinical electrocardiography: Conditions not primarily affecting the heart

Corey Slovis and Richard Jenkins
BMJ 2002 324: 1320-1323. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Rehman, H. u. (2009). Benzylpenicillin potassium. BMJ 339: b4822-b4822 [Full text]  
• Gama, R., Cornes, M., Ford, C. (2009). Avoiding spurious hyperkalaemia. BMJ 339: b4823-b4823 [Full text]  
• Floyd, C. N (2009). Time to flag up "detox" drinks?. BMJ 339: b4824-b4824 [Full text]  

Rapid Responses:

Read all Rapid Responses

Treatment of hyperkalaemia

Charles RV Tomson
bmj.com, 31 Oct 2009 [Full text]

Hyperkalaemia

Habib ur Rehman
bmj.com, 31 Oct 2009 [Full text]

Spurious hyperkalaemia

Charles van Heyningen
bmj.com, 1 Nov 2009 [Full text]

Spurious Hyperkalaemia

L Sam Lewis
bmj.com, 2 Nov 2009 [Full text]

Hyperkalaemia and kEDTA contamination

Rousseau Gama, et al.
bmj.com, 2 Nov 2009 [Full text]

High index of suspicion with timely haemodialysis for hyperkalaemic cardiac arrest

Felix ID Konotey-Ahulu
bmj.com, 5 Nov 2009 [Full text]

Hyperkalaemic 'detox' drinks

Christopher N Floyd
bmj.com, 6 Nov 2009 [Full text]

Hyperkalaemia due to macrogol laxative

Sunku H Guptha, et al.
bmj.com, 6 Nov 2009 [Full text]

Damage to the juxta glomerular apparatus and impairment of aldosterone release.

Richard G Fiddian-Green
bmj.com, 11 Nov 2009 [Full text]

Salbutamol unsafe in hyperkalaemia

Simon B Dimmitt, et al.
bmj.com, 19 Nov 2009 [Full text]

Re: Salbutamol unsafe in hyperkalaemia

Moffat J Nyirenda, et al.
bmj.com, 23 Nov 2009 [Full text]

Online poll

Find out more>>